ReportWire

Tag: COVID-19

  • From groceries to flights to mobile data: Why is Canada so expensive? – MoneySense

    From groceries to flights to mobile data: Why is Canada so expensive? – MoneySense

    [ad_1]

    That doesn’t mean everything costs more in Canada, says David Soberman, a professor of marketing and Canadian national chair of strategic marketing at the University of Toronto’s Rotman School of Management. Canadians may pay more than Americans for the same basket of goods, he says, but we pay less than people in some other countries, like Switzerland. 

    Why do we pay what we do? That’s a difficult question to answer. The reasons are complex and vary depending on the type of good or service. Let’s look at some of the main contributors to Canada’s cost of living, why they are as expensive as they are, and steps you can take to reduce those costs. 

    Why are groceries so expensive in Canada?

    There are a few reasons groceries cost so much in Canada, says Soberman. It’s expensive for companies to ship food products across a country as large as ours, and those costs are reflected in what you pay in stores, he says. But a highly concentrated grocery industry is also a big contributing factor. 

    Canada’s grocery market is dominated by just a few companies. Domestically, there are three big players: Loblaws, Metro and Sobeys. (Some chains, such as Save-On-Foods in Western Canada, compete on a regional basis.) The next largest retailers for grocery sales are Walmart and Costco. Together, these five companies account for more than three-quarters of all food sales in Canada, according to Canada’s Competition Bureau. In 2023, 49% of Canadians report buying groceries from Loblaws or one of its sister stores. 

    Critics argue such concentration allows the dominant companies to participate in anti-competitive practices that ultimately harm consumers through higher prices. In grocery, this takes the form of fixing bread prices, preventing competitors from selling certain products, or collectively deciding when to freeze grocery prices—and when to unfreeze them. It’s a problem experts say applies to other industries, such as telecommunications and air travel. 

    When Canada’s Competition Act was introduced, in 1986, there were at least eight large grocery chains in Canada, each owned by a different company. Since then, more than a dozen major mergers and acquisitions have reduced the level of competition. Today, three big supermarket companies own several smaller chains, including discount brands that could be mistaken for rivals: Loblaws has No Frills, Sobeys has FreshCo and Metro has Food Basics, for example. 

    Source: The Competition Bureau of Canada.

    How does Canada allow for three big grocers to reign? “The law in Canada typically will not allow the Bureau to intervene in these deals, as they are generally seen as unlikely to have a significant impact on prices and other dimensions of competition,” states a Competition Bureau report. “In the case of a major city or suburb, with five or six different grocery stores nearby, it can be hard to prove that removing one option will cause prices to go up significantly.”

    Another underlying issue is that, for many decades, the prevailing view was that “as a small, but large country, we need to accept lower levels of competition to achieve a scale that is necessary to serve the various markets,” says Keldon Bester, executive director of the Canadian Anti-Monopoly Project (CAMP). Over time, that belief has led to fewer and fewer options for consumers, he says.

    [ad_2]

    Justin Dallaire

    Source link

  • Court rules Carnival Cruises was negligent during COVID-19 outbreak linked to hundreds of cases

    Court rules Carnival Cruises was negligent during COVID-19 outbreak linked to hundreds of cases

    [ad_1]

    An Australian court has ruled Carnival Cruises was negligent during an outbreak of COVID-19 onboard one of its ships in March 2020. A class-action lawsuit alleged the cruise line failed to take appropriate measures to ensure passengers on its Ruby Princess ship didn’t get sick as the coronavirus was spreading around the world.

    More than 2,650 passengers were onboard the ship when it departed Sydney on March 8, 2020, and returned to Sydney on March 19.

    Susan Karpik, a former nurse whose husband was hospitalized with COVID-19 after the cruise, was the lead applicant in the class-action suit, according to Shine Law, the firm that represented about 1,000 plaintiffs.

    Karpik sued for over 360,000 Australian dollars, claiming she suffered psychological distress due to her husband’s condition, according to the Reuters news agency. He was given only days to live at one point and is also part of the class-action lawsuit.

    Karpik was awarded AU$4,423.48 ($2,826) for her medical expenses but did not receive other damages. However, attorney Vicky Antzoulatos said her husband and other passengers involved in the suit are still awaiting the court’s decision on their claims and may be awarded more, according to Reuters.

    About 900 COVID-19 cases and 28 deaths were linked to the cruise, Reuters reports.

    During the trial, Carnival argued the nearly 700 U.S. passengers onboard signed a class-action waiver as part of the cruise line’s U.S. terms and conditions and they should not be included in the suit, according to Shine Law. The court has yet make a decision on that.

    “I am pleased with this outcome as it brings a degree of comfort for all passengers who were worse off as a result of traveling on the Ruby Princess,” Antzoulatos said in a news release. “It’s of course only a partial win as 28 lives were lost on this cruise. There are many individuals and families who will never recover from this loss.”

    CBS News has reached out to the law firm for further comment and is awaiting a response.

    “We have seen the judgment and are considering it in detail,” a Carnival Australia spokesperson told CBS News via email. “The pandemic was a difficult time in Australia’s history, and we understand how heartbreaking it was for those affected.”

    In May 2020, Congress opened an investigation into how Carnival responded to COVID-19. At the time, more than 100 U.S. citizens who worked on cruises were stranded on ships because the CDC wanted cruise lines to make quarantine plans before allowing people to disembark.

    Carnival said it was working with the CDC to get the employees home and that it would cooperate with the House investigation.

    The CDC has since stopped monitoring cases of COVID-19 on cruise ships but said in 2022 it would “continue to publish guidance to help cruise ships continue to provide a safer and healthier environment for passengers, crew and communities going forward.”

    [ad_2]

    Source link

  • Long COVID Researchers Make Progress

    Long COVID Researchers Make Progress

    [ad_1]

    A phenomenal amount of research on Long COVID—the name for chronic symptoms following a case of COVID-19—has been published over the past three years. But scientific advances have yet to bring relief to people who are already sick, a group estimated to include about 5% of U.S. adults but hard to precisely quantify due to the difficulty of diagnosing people correctly.

    Researchers are optimistic that breakthroughs are coming. The U.S. National Institutes of Health (NIH) has launched multiple clinical trials focused on potential therapies, and several recent studies have pointed to biomarkers that may help doctors accurately diagnose—and, hopefully, treat—people with Long COVID.

    “In the short history of studying this disease, this is probably the most hopeful moment we’ve ever had,” says Christoph Thaiss, an assistant professor of microbiology at the University of Pennsylvania’s Perelman School of Medicine who co-authored a recent study on Long COVID in Cell.

    The search for biomarkers

    Long COVID is currently a disease mostly defined by its symptoms, which range from brain fog and fatigue to headaches and nervous-system dysfunction. There is no single test that can diagnose it—although recent research points to a variety of potential testing methods, from full-body scans to eye exams.

    A September study published in Nature was widely heralded as a step toward finally having a blood test to confirm Long COVID. Researchers analyzed blood samples from almost 300 people, some of whom had Long COVID, some of whom had never had COVID-19, and some of whom had it and fully recovered. Long COVID patients tended to have low levels of the stress hormone cortisol, and their blood also often suggested that virus lingered in their bodies—either remnants of the virus that causes COVID-19, or other viruses that had been dormant in the body after prior infections and become reactivated.

    Co-author Akiko Iwasaki, an immunobiologist who directs Yale University School of Medicine’s Center for Infection and Immunity, says it’s unlikely there will ever be a single biomarker for Long COVID, since the disease can look very different from person to person. But when a machine-learning model was trained to pick up on all of those potential signals together, it was able to distinguish the blood of Long COVID patients from the blood of people without the condition with 96% accuracy.

    “That doesn’t mean we’re going to have biomarkers next week,” Iwasaki says, “but I think we are moving forward in the right direction.”

    Thaiss’ recent study in Cell found another potential biomarker in the blood of Long COVID patients: low levels of the neurotransmitter serotonin, which is largely produced in the gut and involved in numerous bodily functions. Using stool samples, Thaiss and his colleagues found genetic material from the SARS-CoV-2 virus in the gastrointestinal tracts of a subset of Long COVID patients, mirroring results from other studies. They then hypothesized, and used mice to demonstrate, that this stubborn viral material can trigger an immune response that leads to excess inflammation in the body, in turn hampering the gut’s production of serotonin. Inadequate serotonin seems to contribute to a number of neurological symptoms of Long COVID.

    The study is important because it “gets us closer to understanding what’s happening” in the bodies of people with Long COVID, says Hannah Davis, one of the leaders of the Patient-Led Research Collaborative for Long COVID.

    Low levels of cortisol or serotonin could be useful “signals” for assessing people with Long COVID, but—at least for now—they cannot serve as stand-alone diagnostics, says Dr. Adupa Rao, medical director of the COVID Recovery Clinic at the University of Southern California’s Keck School of Medicine. For one thing, the studies on potential Long COVID biomarkers have been fairly small and must be replicated in larger groups of patients, Rao says. Beyond that, there are plenty of reasons why someone would have low cortisol or serotonin, including non-COVID viral infections, he says.

    Will biomarkers lead to treatments?

    Still, Maayan Levy, who co-authored the Cell study and is also an assistant professor of microbiology at UPenn, believes serotonin may be a target for Long COVID treatment. Building on their findings in mice, her group is designing a clinical trial to test whether selective serotonin reuptake inhibitors (SSRIs)—a widely prescribed class of antidepressant, including fluoxetine (Prozac) and escitalopram (Lexapro), used to boost serotonin levels in the brain—are effective against Long COVID. She also plans to test whether supplementing tryptophan, an amino acid that the body uses to make serotonin, may be beneficial.

    But Davis is skeptical. SSRIs are already so widely used, she says, that “if SSRIs worked, we would know.” And researchers working on ME/CFS, a condition similar enough to Long COVID that many long-haulers meet its diagnostic criteria, have previously warned that tryptophan supplementation may be dangerous for patients. “It would be good to not reinvent the wheel” by re-testing these ideas, Davis says, noting that there is plenty of research on ME/CFS treatment that could inform researchers working on Long COVID.

    In her view, there are other, more promising possible treatments in the research pipeline, including antivirals (which could, in theory, destroy remnants of either reactivated viruses or the SARS-CoV-2 virus lingering in the body); drugs that interact with the immune system; and medications that prevent blood clotting.

    Rao says he’s not sure any drug currently being studied will become a magic bullet, but he’s encouraged by the field’s progress. “My hope is, in the near future, we’ll be able to identify the cause [of Long COVID] and therefore provide more thorough treatment options, rather than treating just the symptoms,” Rao says.

    In Davis’ view, testing treatments may achieve both goals: “Understanding what drugs help patients,” she says, “will also help us understand what’s actually happening in patient bodies.”

    [ad_2]

    Jamie Ducharme

    Source link

  • Head of illicit lab that sparked conspiracy theories arrested, accused of misbranding medical tests

    Head of illicit lab that sparked conspiracy theories arrested, accused of misbranding medical tests

    [ad_1]

    The head of an illegal Fresno County medical testing lab whose underground setup fueled wild conspiracy theories was arrested Thursday, federal prosecutors announced.

    Jia Bei Zhu, who went by a number of aliases, was busted by the U.S. Food and Drug Administration for running the Universal Meditech Inc. lab that manufactured and sold hundreds of thousands of COVID-19, HIV and pregnancy test kits from late 2020 to March 2023 without the required authorizations, according to federal agents.

    Zhu’s lab in Reedley first raised eyebrows in 2022, when a local code enforcement officer discovered it was stocked with vials of blood, jars of urine and about 1,000 white mice living in sullied containers.

    Officials investigated, shut down the lab and ordered the mice euthanized. But after a local news story suggested the mice were bred to carry COVID-19, baseless rumors started flying online that the lab was connected to the Chinese government and could be part of preparations for a biological attack.

    Refrigerators and other equipment inside a now-shuttered medical lab that officials say was operating illegally.

    (Courtesy of city of Reedley / Associated Press)

    But the explanation was more benign.

    The mice were found not to carry COVID-19. They were actually bred to grow the COVID-19 antibody cells used for test kits.

    But authorities allege that the lab was skirting FDA laws and that Zhu, 62, made false statements during the investigation, resulting in him being charged with lying to a federal agent.

    “The disarray at the Reedley lab led to the glare of publicity [Zhu] was trying to avoid, and the ensuing investigation unraveled his efforts to circumvent the requirements that are designed to ensure that medical devices are safe and effective,” said Phillip Talbert, U.S. attorney for the Eastern District of California.

    The Reedley lab was not the first time Zhu’s companies courted trouble.

    In 2016, he was the owner of a Canadian company, IND Diagnostic Inc., that was ordered to pay $300 million “for misappropriating technology related to the separation of sex chromosomes from bull semen,” according to American federal agents.

    Just before his arrest, Zhu was preparing to sue Fresno County for shutting down his lab, the Fresno Bee reported.

    The lab head was reportedly seeking $50 million — alleging the county had wrongly seized medical equipment, including freezers and refrigerators stocked with biological goods.

    [ad_2]

    Noah Goldberg

    Source link

  • Pfizer Will Charge $1,390 For 1 Course Of COVID Drug Paxlovid On Commercial Market

    Pfizer Will Charge $1,390 For 1 Course Of COVID Drug Paxlovid On Commercial Market

    [ad_1]

    Pfizer told pharmacies and clinics this week it will soon price a five-day course of COVID-19 treatment Paxlovid at almost $1,400, more than two-and-a-half times what the federal government has paid for the antiviral pills.

    The Wall Street Journal first reported Wednesday that Pfizer plans to price a course of the oral antiviral at $1,390, far higher than the U.S. had paid at $529. The drug was authorized in the U.S. in 2021 and quickly became a key tool to help treat those at risk of developing severe infections from COVID-19.

    While the figure will be the drug’s list price on the commercial market, many health plans will likely negotiate far better terms that will limit copays or out-of-pocket charges for people who need the pills, the Journal reported.

    Those on Medicare, Medicaid and the uninsured will also still be able to access Paxlovid via the Department of Health and Human Services for free through the end of 2024. HHS added that Pfizer would run a program between 2025 and 2028 for un- and underinsured people to help assist with the cost.

    But as Axios notes, the list price on the commercial market could make it more difficult for patients to access the drug. The U.S. has so far maintained the exclusive purchasing agreement with Pfizer for Paxlovid.

    “Pricing for Paxlovid is based on the value it provides to patients, providers and health care systems due to its important role in helping reduce COVID-19-related hospitalizations and deaths,” a spokesperson for Pfizer told the Journal, adding that many people will pay “as little as $0” under the copay assistance program through 2028.

    Multiple studies have shown reductions in hospitalization for adults who test positive for COVID-19 and are treated with Paxlovid. The Food and Drug Administration gave its full approval to Paxlovid in May, advising treatment for adults with high risk of getting severely ill from COVID-19.

    Pfizer recently cut its sales forecast for the year due to a plunge in Paxlovid prescriptions and sales of its COVID-19 vaccines. Company CEO Albert Burl said recently the U.S. was “in the middle of COVID fatigue, where everyone wants to forget about the disease.”

    [ad_2]

    Source link

  • Using Marijuana May Protect You From COVID-19 – Medical Marijuana Program Connection

    Using Marijuana May Protect You From COVID-19 – Medical Marijuana Program Connection

    [ad_1]

    Using Marijuana May Protect You From COVID-19 Original Author Link click here to read complete story.. … Read More

    [ad_2]

    MMP News Author

    Source link

  • Flu And RSV Could Be On The Rise Nationwide

    Flu And RSV Could Be On The Rise Nationwide

    [ad_1]

    The Centers for Disease Control and Prevention reported on Friday that flu cases are low nationwide, but more could arise in the upcoming weeks.

    “Even these low levels will probably increase in the next couple of weeks,” said Alicia Budd, head of the CDC’s domestic influenza surveillance team, according to NBC News.

    The CDC report shows that by the end of last week, most states in the U.S. had low or minimal flu-related hospital visits. The CDC also has not detected an early rise in flu activity this year as it had last year, NBC News reported.

    But this week, the agency reported an increase in the number of respiratory illness-related hospitalizations. Between May 21 and Oct. 7, the percentage of hospital visits for respiratory illness increased for people ages 0 to 4 years old and 5 to 24 years old, and remained stable for other age groups, according to the CDC report.

    “Given what we saw last year, vaccinating kids is really important to prevent them from getting sick, prevent them from being hospitalized and having the most severe outcomes,” said Danielle Iuliano, senior research epidemiologist at the CDC, according to NBC News.

    The influenza virus is one of several viruses that contribute to respiratory illnesses, such as COVID-19 and respiratory syncytial virus, or RSV, according to the CDC.

    According to ABC News, COVID-19 hospitalizations consistently ticked up in recent months, but are now on the decline nationwide. A CDC spokesperson told HuffPost that RSV-related hospitalizations are increasing among infants, who are susceptible to the virus. Data from WastewaterSCAN indicates that influenza, COVID-19 and RSV are starting to spread at low levels.

    Many hospitals in New York, California and Massachusetts recently restored their mask mandates following the uptick in COVID-19 cases, The New York Times reported. The CDC is recommending that people 6 months and older get a flu shot and COVID-19 booster shot this fall. RSV vaccines are also available for older adults and those who are pregnant.

    [ad_2]

    Source link

  • Say Goodbye To COVID-19 Vaccination Cards. The CDC Has Stopped Printing Them.

    Say Goodbye To COVID-19 Vaccination Cards. The CDC Has Stopped Printing Them.

    [ad_1]

    It’s the end of an era for a once-critical pandemic document: The ubiquitous white COVID-19 vaccination cards are being phased out.

    Now that COVID-19 vaccines are not being distributed by the federal government, the U.S. Centers for Disease Control and Prevention has stopped printing new cards.

    The federal government shipped more than 980 million cards between late 2020, when the first vaccines came out, through May 10, according to the latest available data from the CDC.

    Federal and local health officials don’t expect the discontinuation of the cards to be a particularly big change, since the days of keeping them tucked in purses and wallets to ensure entry into festivals, bars and restaurants are largely over. If you’ve held on to your card, it’s still valid as proof of vaccination. Otherwise, people who need their COVID-19 immunization records will need to request them just like any other vaccine.

    In many cases, the clinic, pharmacy or health department that provided the shot can provide those records. Every state and some cities have an immunization registry, though rules vary on when records are included and options for obtaining copies of your records. Records from the mass vaccination sites held early in the pandemic also should be available in those registries, depending on state laws. There is no national registry for immunization records.

    A nurse practitioner holds a COVID-19 vaccine card at a New York Health and Hospitals vaccine clinic in the Brooklyn borough of New York on Jan. 10, 2021. Now that COVID-19 vaccines are being distributed through the commercial markets instead of by the federal government in 2023, the Centers for Disease Control and Prevention won’t be shipping out any more new cards.

    AP Photo/Craig Ruttle, File

    For example, Texas requires patients’ written consent to be included in the registry, San Antonio Metropolitan Health District spokesman David Andres Alegria said. Other places, including Wyoming and Philadelphia’s city-specific record system, require vaccine providers to log all vaccinations.

    Many states offer digital vaccination records for individuals either online or through an app. Users can save a certificate or a QR code that proves they are vaccinated. And some websites will even track and alert patients when they’re due for another one.

    “One of the positives (during the pandemic) was having increased autonomy on your patient record, especially the immunization record,” said Jeff Chorath, who manages the immunization information system in Washington state. Washington offers two digital options for obtaining vaccination records — a comprehensive list of all of a person’s vaccinations noted in the state database and one specific to COVID-19 vaccines.

    Other states don’t have the same options, so it might take longer to get your records. There could also be gaps in state databases; for example, if you were vaccinated by a federal health provider, those records may be tracked in a separate system.

    As for your old card — if you still have it — maybe don’t mail it off to the Smithsonian quite yet. You should save it like any other health record, Wyoming Department of Health nurse consultant Heidi Gurov said.

    “It’s always good to keep those in a safe spot,” she said.

    Four million people in the U.S. have received the latest COVID-19 vaccine since it was approved last month, CDC director Dr. Mandy Cohen said Wednesday, and a total of 10 million doses have been shipped to providers.

    The Associated Press Health and Science Department receives support from the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

    [ad_2]

    Source link

  • US adds another option for fall COVID vaccination with updated Novavax shots | Long Island Business News

    US adds another option for fall COVID vaccination with updated Novavax shots | Long Island Business News

    [ad_1]

    U.S. regulators on Tuesday authorized another option for fall COVID-19 vaccination, updated shots made by Novavax.

    Updated vaccines from Pfizer and Moderna began rolling out last month, intended for adults and children as young as age 6 months. Now the Food and Drug Administration has added another choice –- reformulated Novavax shots open to anyone age 12 and older.

    The Centers for Disease Control and Prevention already has urged most Americans to get a fall COVID-19 vaccination, shots tweaked to protect against a newer coronavirus strain. Novavax said shots will be available “in the coming days.”

    Protection against COVID-19, whether from vaccination or from an earlier infection, wanes over time. There’s already been a late-summer increase in infections, and health officials hope enough people get the new shots to blunt a winter wave.

    Novavax makes a protein-based vaccine mixed with an immune-boosting chemical, a different technology than the so-called mRNA vaccines made by Pfizer and Moderna.

    While Pfizer and Moderna have shipped millions of doses, the fall rollout so far has been messy since, for the first time, the government isn’t buying and distributing the COVID-19 shots. Ordering confusion from drugstores and doctors’ offices, distribution delays and even bungled paperwork by insurance companies snarled early appointments.

    The updated vaccine versions are supposed to be free through private insurance or Medicare, and the CDC has a program to temporarily provide free shots to the uninsured or underinsured.

    [ad_2]

    The Associated Press

    Source link

  • Federal student loan payments are starting again. Here’s what you need to know | Long Island Business News

    Federal student loan payments are starting again. Here’s what you need to know | Long Island Business News

    [ad_1]

    Federal student loan borrowers will need to start making payments again this month after a three-year-plus pause due to the pandemic.

    You should expect a bill that lays out how much you have to pay each month at least 21 days before your due date. It’s likely that most borrowers have received their bill already but if you have not, visit your loan servicer account. Interest started accruing again in September.

    If you have student loans and haven’t made a payment in the last three years, don’t panic. Here’s what experts recommend:

    WHERE DO I START?

    The first step is to log in to your StudentAid.gov account and check who your loan servicer is. Many loan servicers changed during the pandemic, so you might have a different one than you did back in March 2020, said Amy Czulada, outreach and advocacy manager at the Student Borrower Protection Center.

    Once you know your loan servicer, you’ll log into your account with them to access your student loan balance, monthly payment amount and interest rate. Czulada also recommended that you look at which type of student loan you have, so you know which income-driven repayment plans you might qualify for.

    Lastly, update your personal information in your account with your loan servicer to make sure you receive all important correspondence.

    HOW DO I KNOW WHAT MY PAYMENTS WILL BE?

    Borrowers can find out what their monthly student loan payment will be on their account with their loan servicer. If you don’t know who your servicer is, you can find it by logging in your studentaid.gov account.

    WHAT IF MY PAYMENTS ARE TOO HIGH?

    If you think you’ll have a hard time making payments once they resume, you have several options.

    This summer, President Joe Biden announced a 12-month grace period to help borrowers who struggle after payments restart. You can and should make payments during the first 12 months after payments resume, but if you don’t, you won’t be at risk of default and it won’t hurt your credit score. Interest will accrue whether you make payments or not.

    Betsy Mayotte, president of The Institute of Student Loan Advisors, recommends that you research if you qualify for an income-driven repayment plan. Borrowers can use the loan-simulator tool at StudentAid.gov or the one on TISLA’s website to find a payment plan that best fits their needs. The calculators tell you what your monthly payment would be under each available plan, as well as your long-term costs.

    WHAT’S AN INCOME-DRIVEN REPAYMENT PLAN?

    An income-driven repayment plan sets your monthly student loan payment at an amount that is intended to be affordable based on your income and family size. It takes into account different expenses in your budget, and most federal student loans are eligible for at least one of these types of plans.

    Generally, your payment amount under an income-driven repayment plan is a percentage of your discretionary income. If your income is low enough, your payment could be $0 per month.

    Last year, the Biden administration announced a new income-driven repayment plan. The SAVE plan offers some of the most lenient terms ever. On this plan, interest won’t pile up as long as borrowers make regular payments.

    It’s still possible that the SAVE plan could face legal challenges similar to the one that led the Supreme Court to strike down Biden’s proposal for mass student loan cancellation.

    ARE THERE ANY OTHER PROGRAMS THAT CAN HELP WITH STUDENT LOAN DEBT?

    If you’ve worked for a government agency or a nonprofit, the Public Service Loan Forgiveness program offers cancellation after 10 years of regular payments, and some income-driven repayment plans cancel the remainder of a borrower’s debt after 20 to 25 years.

    Borrowers should make sure they’re signed up for the best possible income-driven repayment plan to qualify for these programs.

    Borrowers who have been defrauded by for-profit colleges may also apply for borrower defense and receive relief.

    If you’d like to repay your federal student loans under an income-driven plan, the first step is to fill out an application through the Federal Student Aid website.

    HOW CAN I REDUCE COSTS WHEN PAYING OFF MY STUDENT LOANS?

    If you sign up for automatic payments, the servicer takes a quarter of a percent off your interest rate.

    HOW DO I ENROLL IN AUTOMATIC PAYMENTS?

    You can enroll in automatic payments through your loan servicer’s account. Borrowers who were enrolled in automatic payments prior to the payment pause need to re-enroll again, said Czulada.

    WHAT ELSE SHOULD I KNOW?

    Czulada recommends staying vigilant about scams. You should never have to pay to get help with your loans or to apply for any programs.

    “The Department of Education will never call you on the phone. So, if you’re getting a phone call that says ‘Hey, pay $100 now and you’ll get your debt canceled,’ that’s a red flag that it’s a scammer,” said Czulada.

    To protect yourself from scams, the Department of Education recommends that you know their official email addresses, check for typos in advertisement and never share your log-in information.

    [ad_2]

    The Associated Press

    Source link

  • How FDA’s top vaccines official is timing his COVID booster and flu shot for fall 2023

    How FDA’s top vaccines official is timing his COVID booster and flu shot for fall 2023

    [ad_1]

    A top-ranking Food and Drug Administration official, responsible for overseeing the approvals of the new vaccines now rolling out for this fall and winter’s three respiratory virus threats, said this month he is personally planning to space out his vaccinations over the coming weeks. 

    “Some people are saying, ‘Well, could I get RSV, COVID and the flu vaccine on the same day?’ Yes, indeed, you could. But honestly, I might not,” said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. 

    Instead, he said he intended to get the COVID shot right away and the flu shot in early October.

    Marks, who was speaking during a recent call with FDA stakeholders, stressed that he did not disagree with guidance from the Centers for Disease Control and Prevention which allows giving multiple different routine shots during the same visit. Doctors refer to this as “coadministration” or “simultaneous administration” of vaccines.

    However, he acknowledged that getting up to three of the different vaccines at the same time could lead to more side effects — like stronger fatigue or a small fever — in the days after getting the shots. 

    Spacing out the shots by around two weeks could “minimize the chance of interactions, and minimize confusing side effects from one with another,” he said. They might be a good option for people who did not mind multiple trips to the pharmacy or their doctor’s office.

    “I might just want to space them out a little bit. But if you had to drive a lot of miles to get the vaccines, then it might not be unreasonable to get all three of them at once,” said Marks.

    Getting an updated COVID-19 vaccine now

    Of the currently available options, Marks said that his plan was to get a dose of the updated COVID-19 vaccine first.

    Health authorities have been fortunate to have a vaccine that appears likely to work well for protecting against the currently circulating strains of the virus, he said.

    “It’s like having a bird in the hand. I have a bird in the hand, good match, a lot of COVID around, great time to go get vaccinated,” said Marks. 

    The FDA had selected the strain to target in the current batch of shots back in June, clearing the way for vaccine makers to ramp up their production ahead of a fall rollout. 

    Marks cited recent data suggesting that these updated vaccines, which have been revised from previous designs to now target the XBB.1.5 strain of the virus, would also work to boost protection against its closely-related descendants now dominant nationwide.

    Early results shared by the vaccine makers with a CDC panel earlier this month also suggests that these updated shots will also work against the highly mutated BA.2.86 variant, which has been reported in a growing number of states. 

    Several leading COVID trends, like emergency department visits, have started to slow in recent weeks following a summer wave that began to accelerate last month. Another “moderate” wave is predicted to begin over the coming colder months, the CDC’s disease forecasters say, with that surge’s peak expected to arrive potentially earlier than it did last season.

    Marks said it was possible that health authorities might allow for another dose to be offered to some vulnerable groups later in the fall and winter. 

    “I think if we saw that it appeared that people might benefit in a few months from an additional dose, we would probably work with our CDC colleagues to issue a recommendation at that time. But right now we are just talking about a single recommendation, a single dose,” he said.

    Scheduling a flu shot for early October

    By early next month, Marks said he plans to have received his flu shot. 

    “I usually get my influenza vaccine around October 1st,” Marks said. 

    This is later than some other health officials within the Biden administration. CDC Director Dr. Mandy Cohen posted on social media on Sept. 6 to say she had gotten vaccinated for the flu.

    Similar to previous seasons, CDC’s official recommendations for this year are that “[flu] vaccination should ideally be offered during September or October.” 

    Marks said that the boost in protection offered by flu vaccines can wane, underscoring why the shots should not be given too early in the season, before the threat of infections ramps up. Flu season in the U.S. typically peaks between December and February, but can stretch into the spring.

    The protection from a flu shot “has a little bit of a shorter life than we might like, in some ways it’s a little like the COVID vaccines,” Marks said.

    Right now, weekly CDC data suggests flu activity remains at low levels in most parts of the country. 

    New options for RSV

    Some Americans also have new options to be immunized for RSV, or respiratory syncytial virus, for the first time this year. 

    Older adults, ages 60 and older, can get a dose of the new vaccines developed by Pfizer or GSK. The CDC recommends that shots be offered “as early as vaccine supply becomes available” this year.

    CDC data suggests RSV infections have begun to accelerate in some parts of the country, with the steepest rises in the Southeast. 

    A panel of CDC advisers on Friday recommended that Pfizer’s new RSV vaccine should be given during pregnancy as well, in hopes of passing on protection to newborns during their most vulnerable early months of life. The panel recommended that pregnant people take one dose of the vaccine between weeks 32 and 36 of pregnancy. 

    A new antibody injection from Sanofi and AstraZeneca is also available for babies this year, which is recommended to be given to infants born ahead of this coming RSV season.

    [ad_2]

    Source link

  • Ron DeSantis Rules Out Funding COVID Boosters If He Becomes President

    Ron DeSantis Rules Out Funding COVID Boosters If He Becomes President

    [ad_1]

    Florida Gov. Ron DeSantis (R) on Wednesday said the U.S. government will not pay for COVID boosters if he gets elected president in 2024.

    “Certainly we’re not going to fund them,” DeSantis told “ABC News Live Prime.”

    His comments came after Florida advised residents under age 65 to skip the updated COVID-19 vaccine this fall, even though coronavirus hospitalizations and deaths related to the virus are rising across the U.S.

    DeSantis took issue with the studies done on the mRNA boosters, claiming “they have not demonstrated the benefit” of the shots.

    ABC News’ Linsey Davis pressed DeSantis on the issue, noting his remarks contradict the guidance of the Centers for Disease Control and Prevention. The CDC recommends that anyone over 6 months old receive an updated mRNA COVID vaccine manufactured by either Pfizer or Moderna.

    The Florida Republican, who is currently trailing in the 2024 presidential race, proceeded to attack the health agency, saying the American people have lost faith in it.

    “The trust that’s been lost, I think, has been incalculable. And one of the things that I said is when I come in, we’re going to have a reckoning about all these COVID policies,” DeSantis said. “We’re going to hold people accountable who got it wrong.”

    Biden, on the other hand, has backed the CDC’s recommendations and urged Americans to stay up to date on their vaccinations.

    The CDC’s Advisory Committee on Immunization Practices approved the latest COVID-19 booster earlier this month, shortly after the Food and Drug Administration authorized the updated vaccine.

    But Florida’s surgeon general, Dr. Joseph A. Ladapo, last week expressed skepticism about the safety of those shots.

    “I just think that at this point, with the amount of immunity that’s in the community, with virtually every walking human being having some degree of immunity, and the questions we have about safety and about effectiveness ― especially about safety ― my judgment is that it is not a good decision for young people and for people who are not at high risk, at this point in the pandemic,” he said.

    CDC Director Dr. Mandy Cohen has rebutted Ladapo’s criticism, saying both her agency and the FDA have reviewed the shots.

    “Public health experts are in broad agreement about these facts, and efforts to undercut vaccine uptake are unfounded and dangerous,” Cohen said.

    COVID cases appear on the rise across the country. The CDC reported COVID hospitalizations were up 7.7% for the week ending Sept. 9, while COVID-related deaths increased by 4.5% during the same period.

    Meanwhile, DeSantis has been struggling to get traction for his presidential bid.

    A new poll released Wednesday by CNN and the University of New Hampshire showed the governor down by 13% compared to the last survey done in the state in July. Apart from former President Donald Trump, DeSantis now also appears to be trailing businessman Vivek Ramaswamy, former United Nations ambassador Nikki Haley and former New Jersey Gov. Chris Christie when it comes to the respondents’ first choice for GOP nominee in New Hampshire.

    [ad_2]

    Source link

  • U.S. will again offer free at-home Covid tests starting Monday

    U.S. will again offer free at-home Covid tests starting Monday

    [ad_1]

    Covid-19 home test kits are pictured in a store window during the Covid-19 pandemic in the Manhattan borough of New York City, Jan. 19, 2022.

    Carlo Allegri | Reuters

    The Biden administration on Wednesday said it will resume offering free at-home Covid tests to American households Monday as the virus gains a stronger foothold nationwide. 

    Americans will soon be able to use COVIDtests.gov to request four free tests, the administration said in a release. 

    The government had offered free test kits through that website since January 2022, but the site stopped taking orders June 1 of this year to conserve supplies of the tests. 

    The government is relaunching the program in time for the fall and winter when the virus typically spreads at higher levels. Covid hospitalizations have already increased for eight straight weeks — an uptick primarily driven by newer strains of the virus.

    But the Biden administration noted that the at-home tests set to be delivered will detect currently circulating Covid variants. The kits are intended for use through the end of 2023 and will come with instructions for how people can verify if a test’s expiration date has been extended, the administration added.

    Testing is a critical tool for protection as Covid infections climb again. But lab PCR tests — the traditional method of detecting Covid — have become more expensive and less accessible for some Americans since the U.S. government ended the public health emergency in May. 

    The end of that declaration also changed how public and private insurers cover at-home tests, potentially leaving some people unable to get those tests for free through their plans. But certain local health clinics and community sites still offer at-home tests to the public at no cost. 

    Also on Wednesday, the Biden administration said it will provide $600 million to strengthen manufacturing capacity at 12 Covid test manufacturers across the country. The administration expects to secure about 200 million tests from those companies. 

    “These critical investments will strengthen our nation’s production levels of domestic at-home COVID-19 rapid tests and help mitigate the spread of the virus,” Health and Human Services Secretary Xavier Becerra said in a statement.

    [ad_2]

    Source link

  • The Federal Reserve leaves rates unchanged. Here’s how it impacts your money

    The Federal Reserve leaves rates unchanged. Here’s how it impacts your money

    [ad_1]

    The Federal Reserve left its target federal funds rate unchanged Wednesday, but did not signal an end to its aggressive rate hike campaign.

    For households, that offers little relief from sky-high borrowing costs.

    Altogether, Fed officials have raised rates 11 times in a year and a half, pushing the key interest rate to a target range of 5.25% to 5.5%, the highest level in more than 22 years. 

    “I’m worried for the consumer,” said Tomas Philipson, University of Chicago economist and a former chair of the White House Council of Economic Advisers. “People are hit on both fronts — lower real wages and higher rates.”

    More from Personal Finance:
    3 money moves millionaires are more likely to make
    Money market funds vs high-yield savings accounts
    Homeowners say 5% is the magic number to move

    Since wage growth for many Americans hasn’t been able to keep pace with higher prices, those households are getting squeezed and are going into debt just when borrowing rates are spiking, Philipson said.

    Real average hourly earnings fell 0.5% in August, while borrowers are paying more on credit cards, student loans and other types of debt.

    “Borrowing is very expensive, period,” Philipson said.

    What the federal funds rate means for you

    The federal funds rate, which is set by the central bank, is the interest rate at which banks borrow and lend to one another overnight. Although that’s not the rate consumers pay, the Fed’s moves still affect the borrowing and savings rates they see every day.

    Here’s a breakdown of how the central bank’s increases so far have affected consumers:

    Credit cards

    Since most credit cards have a variable rate, there’s a direct connection to the Fed’s benchmark. As the federal funds rate rose, the prime rate did as well, and credit card rates followed suit.

    Credit card annual percentage rates are now more than 20%, on average — an all-time high. Further, with most people feeling strained by higher prices, more cardholders carry debt from month to month.

    For those who carry a balance, there’s not much relief in sight, according to Matt Schulz, chief credit analyst at LendingTree.

    “Even though the Fed chose not to raise rates in September, the truth is that no one should expect credit card interest rates to stop rising anytime soon,” he said.

    In the meantime, knocking down that debt “should absolutely be the goal,” he said.

    Home loans

    Although 15-year and 30-year mortgage rates are fixed, and tied to Treasury yields and the economy, anyone shopping for a new home has lost considerable purchasing power, partly because of inflation and the Fed’s policy moves.

    The average rates for a 30-year, fixed-rate mortgage “remain anchored north of 7%,” said Sam Khater, Freddie Mac’s chief economist.

    “The reacceleration of inflation and strength in the economy is keeping mortgage rates elevated,” he said.

    Other home loans are more closely tied to the Fed’s actions. Adjustable-rate mortgages and home equity lines of credit, or HELOCs, are pegged to the prime rate. Most ARMs adjust once a year after an initial fixed-rate period. But a HELOC rate adjusts right away. Already, the average rate for a HELOC is up to 9.12%, the highest in 22 years, according to Bankrate.

    “That HELOC is no longer low-cost debt and it warrants a much higher focus on repayment than it has for a long time,” said Greg McBride, chief financial analyst at Bankrate.com.

    Auto loans

    Even though auto loans are fixed, payments are getting bigger because the price for all cars is rising along with the interest rates on new loans.

    The average rate on a five-year new car loan is now 7.46%, the highest in 15 years, according to Bankrate.

    Experts say consumers with higher credit scores may be able to secure better loan terms or shop around for better deals. Car buyers could save an average of $5,198 by choosing the offer with the lowest APR over the one with the highest, according to a recent report from LendingTree. 

    Student loans

    Federal student loan rates are also fixed, so most borrowers aren’t immediately affected by the Fed’s moves. But undergraduate students who take out new direct federal student loans are now paying 5.50% — up from 4.99% in the 2022-23 academic year and 3.73% in 2021-22.

    For those with existing debt, interest is now accruing again as of Sept. 1. In October, millions of borrowers will make their first student loan payment after a three-year pause.

    Private student loans tend to have a variable rate tied to the Libor, prime or Treasury bill rates — and that means that those borrowers are already paying more in interest. How much more, however, varies with the benchmark.

    Savings accounts

    While the central bank has no direct influence on deposit rates, the yields tend to be correlated to changes in the target federal funds rate. The savings account rates at some of the largest retail banks, which were near rock bottom during most of the Covid pandemic, are currently up to 0.43%, on average, according to the Federal Deposit Insurance Corp.

    Thanks, in part, to lower overhead expenses, top-yielding online savings account rates are now paying over 5%, according to Bankrate, which is the most savers have been able to earn in more than 15 years.

    Because the top online savings accounts are currently beating inflation, “money in a savings account is no longer a drag on your portfolio,” McBride said. And yet, only 22% of savers are earning 3% or more on their accounts, according to another Bankrate report.

    “Boosting emergency savings is rewarded with returns exceeding 5%, if you’re putting the money in the right place,” McBride said.

    Subscribe to CNBC on YouTube.

    [ad_2]

    Source link

  • New COVID variant BA.2.86 spotted in 10 states, though highly mutated strain remains rare

    New COVID variant BA.2.86 spotted in 10 states, though highly mutated strain remains rare

    [ad_1]

    People across at least 10 states have now been infected by BA.2.86, a highly mutated variant of the virus that causes COVID-19 that authorities have been closely tracking.

    According to data tallied from the global virus database GISAID, labs have reported finding BA.2.86 in samples from Colorado, Maryland, Michigan, New York, Ohio, Oregon, Pennsylvania, Texas, Virginia and Washington.

    Estimates suggest BA.2.86 still remains a small fraction of new COVID-19 cases nationwide. 

    Too few sequences of the virus have been reported to show up on the Centers for Disease Control and Prevention’s biweekly variant estimates, which still show that a long list of closely related XBB variant descendants are driving virtually all infections around the country. 

    “The diversity is less than what appears. Many of these lineages actually have identical spike sequences. We’ve observed this before, where we see convergent evolution and viruses evolving to have the same substitutions,” said Natalie Thornburg, a laboratory branch chief in the CDC’s Coronaviruses and Other Respiratory Viruses Division.

    Thornburg, who was speaking at a meeting of the agency’s vaccine advisers last week, said it was still too early to know “if BA.2.86 will be of any significant circulation.”

    Health authorities do believe BA.2.86 is continuing to spread widely around the world, after scientists first voiced concern in August over the strain’s large number of mutations. 

    “We are concluding this because some of the people infected with BA.2.86 do not have known links to other infected individuals and did not recently travel to an area with known cases of illness from BA.2.86,” the CDC said Friday in a risk assessment.

    Several countries have reported finding the variant in either wastewater samples or tests from people infected, including provinces in Canada. CDC’s airport testing program has also picked up signs of the strain in arriving travelers from abroad.

    While it remains too early to say how transmissible the variant could be compared to other strains on the rise, officials say BA.2.86 has so far proved it has the ability to drive outbreaks. 

    Nearly two dozen nursing home residents were infected by the BA.2.86 variant in a cluster of cases late last month, officials in the United Kingdom reported.

    “At this point, although we’ve got limited clinical data, on the cases who have been reported, there isn’t evidence that it is causing more severe illness. But it’s something we’ll continue to track,” Hanna Kirking, of the CDC’s COVID-19 epidemiology task force, said Thursday at an event hosted by the Infectious Diseases Society of America.

    Could BA.2.86 drive a new surge this winter?

    The CDC has described early research findings as “reassuring” about the variant so far, suggesting it might not be as capable of evading the body’s immune defenses as initially feared. 

    Vaccine manufacturers have also said their data suggest the updated COVID-19 shots now being rolled out should also work against BA.2.86.

    Research on BA.2.86 so far has so far largely relied on pseudoviruses, which are other viruses mocked up in a lab to mimic BA.2.86’s distinctive mutations. Better findings will need to use viruses grown from actual samples of infected patients, a process which is now underway.

    “CDC has generated two authentic isolates of BA.2.86. One confirmed and one putative. We are in the process of distributing BA.2.86 viruses to multiple labs to do transmission studies, more neutralization studies, against lots of different kinds of sera,” said Thornburg.

    For now, officials have expressed “guarded hope” about signs the current late summer wave of COVID-19 driven by other variants has passed its peak. One leading indicator of the virus — emergency department visits — has been trending down in recent weeks.

    Past years have seen renewed upticks of the virus return in the colder months, alongside influenza and RSV, or respiratory syncytial virus. The CDC says it’s too early to figure out how the BA.2.8 variant will factor into its modeling for the coming respiratory virus season. 

    Meanwhile, scientists have already tracked BA.2.86 beginning to evolve into at least two different branches. Cases from both sublineages have been spotted in the U.S. so far, among the handful of cases reported globally so far.

    “That’s likely the tip of the iceberg, given that we know we don’t have complete sequencing coverage,” Kirking said.

    [ad_2]

    Source link

  • Looking for the new COVID vaccine booster? Here’s where to get the shot.

    Looking for the new COVID vaccine booster? Here’s where to get the shot.

    [ad_1]

    Pharmacies across the U.S. have started administering new COVID-19 booster formulations from drugmakers Pfizer and Moderna.

    The Food and Drug Administration approved the revised mRNA vaccine shots Monday as several COVID variants spread and hospitalizations rise. The Centers for Disease Control and Prevention recommends the shots for everyone 6 months and older. The vaccine is similar to previously approved formulas but it was updated to target the XBB variants that became prevalent last winter.

    Spokespeople for Moderna and Pfizer said people who want to get booster shots can contact pharmacies and hospitals directly for an appointment. 

    “Moderna’s updated COVID-19 vaccine is being shipped to major retail pharmacies nationwide, and consumers can reach out to them directly to make their vaccination appointments,” a Moderna spokesperson said in a statement to CBS MoneyWatch. 

    Pfizer said it has been “manufacturing this season’s vaccine in advance of the FDA’s decision to ensure supply readiness ahead of the fall and winter season. Doses will be available in pharmacies, hospitals and clinics across the U.S.”

    Here’s more information on where to get the latest COVID vaccine.

    CVS

    CVS on Wednesday announced that the newly authorized vaccines were in stock and available to consumers at its pharmacies. 

    “Pharmacies and retail medical clinics will begin receiving the new vaccine today and will continue to receive inventory on a rolling basis throughout the week,” the drugstore chain said in a statement.

    CVS said it expects all pharmacy locations across the U.S. to have doses of the new vaccine in stock by early next week. You can make an appointment at CVS.com or simply got to the most convenient location. If pharmacies have the vaccine in stock, they’ll accept walk-ins.

    Rite-Aid

    A Rite-Aid spokesperson said it expects to have the updated COVID vaccine in all of its pharmacy locations “soon,” without specifying exactly when. 

    Customers can schedule appointments beginning Friday. Walk-ins will be permitted once the vaccine becomes available in its stores. 

    Walgreens

    Walgreens told CBS MoneyWatch that it is now offering the jabs at locations nationwide. Consumers can schedule appointments immediately, with the first openings falling on Monday of next week. 

    Walgreens may add earlier appointments if vaccine supplies arrive earlier than expected. Doses of both brands’ formulas are currently being shipped to the company’s locations nationwide. 

    As with previous versions of the COVID-19 vaccine, the shots are available at no cost to consumers. 

    Because the CDC’s Advisory Committee on Immunization Practices has recommended the vaccine for children, the government is required to administer it to kids as well as commercially insured adults for free.

    The federal government’s Bridge Access Program will also cover the cost of shots for the 25 million to 30 million uninsured adults in the U.S., according to KFF Health News. The program will pay for pharmacies like Walgreens and CVS to provide the shots for free, while Pfizer and Moderna will also donate a certain number of doses, according to the CDC. 

    Visit Vaccines.gov to identify pharmacies with available doses, as well as those participating in the Bridge Access Program.

    [ad_2]

    Source link

  • CDC recommends updated COVID boosters aimed at new variants

    CDC recommends updated COVID boosters aimed at new variants

    [ad_1]

    CDC recommends updated COVID boosters aimed at new variants – CBS News


    Watch CBS News



    The CDC is recommending the new COVID booster shot universally for anyone older than 6 months after its panel of outside vaccine advisers endorsed it. Dr. William Schaffner, professor of infectious diseases at Vanderbilt University Medical Center, joined CBS News to talk about the new booster shots.

    Be the first to know

    Get browser notifications for breaking news, live events, and exclusive reporting.


    [ad_2]

    Source link

  • CDC Panel Approves New COVID-19 Booster Amid Rapid Spread Of New ‘Eris’ Subvariant

    CDC Panel Approves New COVID-19 Booster Amid Rapid Spread Of New ‘Eris’ Subvariant

    [ad_1]

    A U.S. Centers for Disease Control and Prevention panel has approved the latest booster for COVID-19 as cases continue to rise amid the spread of the virus’ omicron variants.

    The panel approved the updated vaccine on Tuesday, universally recommending that everyone six months and older receive the shot, which more closely matches the currently circulating variants. CDC Director Mandy Cohen still needs to endorse the approval, but has previously said she expects the booster to roll out this month.

    The Advisory Committee on Immunization Practices’ approval comes a day after the Food and Drug Administration authorized the updated vaccine, which targets, among others, the XBB.1.5 subvariant of omicron nicknamed “Kraken.” The emergency use authorization applied to boosters manufactured by Pfizer and its German partner BioNTech SE, as well as by Moderna. The XBB.1.5 monovalent vaccines are expected to be available in the coming days, according to Moderna.

    The FDA is still reviewing a vaccine booster manufactured by Novavax, according to the company. Novavax claims it would provide the only protein-based COVID-19 vaccine in the U.S., compared to Pfizer and Moderna’s mRNA vaccines.

    The boosters come amid a surge in COVID-19 cases, with the EG.5 subvariant ― nicknamed “Eris” ― currently causing the majority of cases in the United States. The CDC says that COVID-19 hospitalizations grew by almost 16% the week ending Aug. 26, while COVID-19 deaths increased by more than 10% in the week ending Sept. 2.

    Moderna and Pfizer confirmed their new boosters are effective against Eris, as well as the BA.2.86 strain.

    The U.S. government ended the COVID-19 public health emergency in May, handing the responsibility of vaccinations over to the private sector. Moderna told the CDC that its new vaccine will be sold at $129 per dose, and Pfizer said its vaccine will be $120 dose. Novavax said that its vaccine would be sold at $130 per dose, but that its contracted price with the CDC is $72.50 per dose.

    The vaccines are still expected to be free for most Americans who are covered by health insurance.

    Dr. Anthony Fauci, one of the country’s top infectious disease experts and President Joe Biden’s former chief medical adviser, said on Sunday that there is “no doubt” the U.S. is experiencing a rise in COVID-19 cases. But while he is continuing to monitor the uptick, Fauci predicted the country will not be overwhelmed by the virus this winter compared to previous years.

    “I think none of us in the public health field are predicting that this is going to be a tsunami of hospitalizations and deaths the way we saw a year or more ago,” he said, stressing that most Americans have COVID-19 antibodies through vaccinations and disease-induced immunity.

    [ad_2]

    Source link

  • FDA signs off on updated COVID boosters. Here’s what to know about the new vaccine shots for fall 2023.

    FDA signs off on updated COVID boosters. Here’s what to know about the new vaccine shots for fall 2023.

    [ad_1]

    The Food and Drug Administration signed off on updated COVID-19 vaccine and booster shots Monday, moving one step closer to making the new shots available for the public to get boosted for the fall virus season. The decision comes amid an increase in COVID hospitalizations and concern about the spread of several new variants

    “The public can be assured that these updated vaccines have met the agency’s rigorous scientific standards for safety, effectiveness, and manufacturing quality. We very much encourage those who are eligible to consider getting vaccinated,” Dr. Peter Marks, director of FDA’s Center for Biologics Evaluation and Research, said in a news release announcing the move. 

    The FDA said it would greenlight the updated vaccines for Americans as young as 6 months old from Moderna and Pfizer. 

    However, like with other vaccines, most vaccinations will not be available until after a panel of the Centers for Disease Control and Prevention’s outside vaccine advisers also weighs in on new recommendations. The CDC’s Advisory Committee on Immunization Practices is scheduled to vote Tuesday afternoon on the updated shots. 

    “We expect this season’s vaccine to be available in the coming days, pending recommendation from public health authorities, so people can ask their doctor about receiving their COVID-19 vaccine during the same appointment as their annual flu shot,” Albert Bourla, chairman and CEO at Pfizer, said in a statement.

    The new shots are similar to previously approved formulas but were updated to target the XBB variants — strains of the virus descended from the original Omicron variant — which became dominant last winter. 

    Newer descendant strains have since emerged, though vaccine makers have announced early findings suggesting their shots will also work for the latest strains on the rise, including BA.2.86

    “The upcoming, updated COVID booster shots still provide the best protection we have against the disease, especially the most severe forms of COVID,” Emily Smith, a global health expert and author of “The Science of the Good Samaritan,” told CBS News in an email. “Even though we continue to have new variants of COVID pop up, the good news is that the updated booster shots still work against the current variants circulating, including the newest variants.”

    Smith says her whole family, including her children, will get the booster shots when they’re available.

    “With the recent surge in cases and projected surges this fall, now is the time to get your vaccines,” she added.

    When will the new COVID booster be available?

    Shots from Pfizer and Moderna can begin shipping out this week following the FDA’s authorizations and approvals for the revised mRNA vaccines.

    Vaccinators have already been pre-ordering doses. The shipments mark the first largely purchased and delivered through the traditional commercial market, instead of the government-bought supplies from earlier in the pandemic.

    While the FDA’s move also means vaccinators can legally begin offering the shots, most will likely wait until the CDC also weighs in with its recommendations on the revised vaccines. That is a key step to guarantee federal liability protections for vaccinators. 

    The Biden administration has said it plans to continue offering its online search portal to find COVID-19 vaccinations. However, for Americans with private insurance, whether their plans cover options on that website may vary between insurers.

    A third option is also expected to roll out later this year from Novavax; the company announced last month it was also seeking the FDA’s authorization for an update to its COVID vaccine. Pfizer and Moderna had already completed their requests earlier in the summer.

    “Novavax is currently responding to the FDA’s requests to facilitate final review, and timing is ultimately at the discretion of the FDA,” the vaccine maker said in a release Monday.

    Are COVID boosters still free?

    For Americans with insurance, COVID-19 vaccines will remain free through in-network providers, similar to the annual flu shot.

    Under a law passed early in the pandemic, private insurers have been required to cover COVID-19 vaccines “immediately upon the vaccine becoming authorized or approved” by the FDA. This is different than other vaccines, which insurers typically have several months to implement coverage for.

    For Medicare, seniors will continue to pay nothing for their COVID-19 vaccinations from any providers that accept Medicare assignment, a Centers for Medicare and Medicaid Services spokesperson said. Medicare Advantage beneficiaries also will also not have to pay anything, as long as they get their shots from an in-network provider.

    For uninsured Americans, the Biden administration aims to offer shots for free through its “Bridge Access Program” at health centers, local health departments and eventually pharmacies.

    Who should get the shots?

    The FDA says virtually all Americans as young as 6 months old are now approved or authorized to get at least one dose from either Pfizer or Moderna from their updated formulation.

    However, while virtually all Americans are now eligible to get the shots, recommendations on when and who it’s most important for will be up for the CDC’s ACIP to consider on Tuesday.

    Not all experts agree on whether everyone should be recommended to get the new shots, or just those at higher risk of severe disease.

    John Moore, a professor of microbiology and immunology at Weill Cornell Medical College, told KFF Health News that he saw the new shots as “not remotely a game changer.”

    For healthier adults and children, “it’s a boost in protection for a few months,” Moore said.

    [ad_2]

    Source link

  • FDA approves new COVID boosters

    FDA approves new COVID boosters

    [ad_1]

    FDA approves new COVID boosters – CBS News


    Watch CBS News



    The FDA has approved new COVID-19 boosters designed to target the current dominant variant. The new shots could roll out as early as this week if the Centers for Disease Control and Prevention also approves them.

    Be the first to know

    Get browser notifications for breaking news, live events, and exclusive reporting.


    [ad_2]

    Source link